BioSpace News Archive

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 12th Annual LD Micro Main Event on Wednesday, December 11, 2019

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2019 Cross-Border Healthcare Winter Summit on Tuesday, December 10, 2019

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present a corporate overview at the 12th Annual LD Micro Main Event on Tuesday,

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Breast Health Solutions suite will be available on the Nuance® AI Marketplace.

Global Blood Therapeutics, Inc. announced that on December 1, 2019, the compensation committee of GBT’s board of directors granted 21 new employees options to purchase an aggregate of 13,000 shares of the company’s common stock with a per share exercise price of $66.50 and restricted stock units for an aggregate of 58,875 shares of the company’s common stock.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.

Deloitte and Tisch MS Research Center of New York (Tisch MSRCNY) are using data science, artificial intelligence (AI) and machine learning in a multiphase research project to find patterns that may relate to the cause of multiple sclerosis (MS).

Organizations will use next-generation costing system to help executives, analysts and physicians understand and evaluate the true cost of patient care

OptiScan Biomedical Corporation, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU), today announced the online publication of two peer-reviewed papers highlighting key benefits delivered by the company’s OptiScanner continuous monitoring platform for intensive care units.

Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.